BioSpace News Archive

[Pamplona, Covina] - The Foundation for Prader Willi Research (FPWR) has provided a new venture philanthropy award, in the form of a convertible loan, to Palobiofarma S.L., a Spanish biopharmaceutical company focused on developing innovative treatments for serious diseases.

American Aires Inc. (CSE: WIFI) (OTC Pink: AAIRF) (“Aires” or the “Company”), a leader in scientifically-proven EMF modulation technology, is excited to announce significant progress on a global technology patent that bolsters its intellectual property portfolio.

Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS) today announced that it will report financial results for the first quarter ended March 31, 2023, on Thursday, May 4, 2023 after the close of the US market.

Eagle Pharmaceuticals, Inc. (“Eagle” or the “Company”) (Nasdaq: EGRX) today announced that the Company will release its first quarter 2023 financial results on Tuesday, May 9, 2023, before the market opens.

IntelGenx Technologies Corp. announces that it has received conditional approval from the Toronto Stock Exchange to extend the expiry date of warrants originally issued to Cantone Research Inc. on August 5, 2021.

Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS), today announced that an abstract related to its TSHA-102 program in Rett syndrome was accepted for presentation at the upcoming American Society of Gene and Cell Therapy (ASGCT) 26th Annual Meeting.

Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it will report first quarter 2023 financial results after the U.S. financial markets close on Thursday, May 4, 2023.

Specialty cancer diagnostics company Precipio, Inc., announces notification by the NASDAQ Stock Market that the Company has been granted a 180-day extension to allow the Company to meet the required minimum $1.00 per share closing bid price of its common stock for 10 consecutive business days for continued inclusion on the Nasdaq Capital Market Exchange.

Tempest Therapeutics, Inc. (Nasdaq: TPST) today announced the company plans to report early data from its Phase 1b/2 combination study of TPST-1120 in first-line hepatocellular carcinoma in a premarket press release and webcast Friday, April 28, 2023.

AptarGroup, Inc., a global leader in drug delivery, consumer product dispensing and active material science solutions and services, reported strong operational performance driven by Aptar’s Pharma and Beauty segments.